Astrazeneca Share Discussion Threads

[onehanded] 17/3/2021 07:18

Bet ASTRA looking at this small UK comany.....

wow a new 60 second breath test for covid and 40 other conditions in real time and result sent to app from Deepverge DVRG

so big news for Deepverge DVRG today, and not in the share price 60 second test for covid in a breath sample and 40 other conditions for complete all round real time monitoring. Read the RNS to see how big this will be.

[holts] 17/3/2021 07:07

Looking at what's stats I can find there has been one case in 11 million in the UK to date , it is evident that there is for some reason in Europe political interference in these decisions . It may well be the case that they are short of supplies but to impose. a suspension seems almost suicidal it will kill far far more people if they do not get a vaccination . Macron indirectly started this ball rolling.

[buywell3] 17/3/2021 04:28

P/E .... 41.2

[philanderer] 17/3/2021 00:19

Telegraph market report..

"AstraZeneca shares jump on European backing for vaccine"

[bluemango] 16/3/2021 20:49

Different take, rather more positive on it going ahead:

AstraZeneca Pops On Alexion Buyout Despite Mounting Covid Vaccine Doubt

ALLISON GATLIN 04:31 PM ET 03/16/2021
AstraZeneca stock jumped Tuesday after the company affirmed its plan to acquire Alexion Pharmaceuticals (ALXN) in the third quarter, even as more European countries suspended use of AstraZeneca's (AZN) Covid vaccine.

In a filing with the U.S. Securities and Exchange Commission, AstraZeneca said it withdrew its notification of the pending merger with the Federal Trade Commission. That restarts a 30-day clock and gives the FTC more time to review the proposed transaction, Wedbush analyst Laura Chico said in a report to clients.

Still, the companies reaffirmed their plan to wrap the $39 billion deal in the third quarter, boosting AstraZeneca stock.

[essentialinvestor] 16/3/2021 20:31

I would much prefer the merger completes, there is near 0 product
overlap. Market may prefer for this to fall apart, as per the sharp sell
off on the initial announcement.

[bluemango] 16/3/2021 20:24

#4354 Presumably this story (for those who want to sign up to read full article - I haven't):

[holts] 16/3/2021 20:14

Why is it seemingly the case that the clots in the head are not being found in the UK program ?

[smcni1968] 16/3/2021 20:09

Alexion deal might not get approval from the government according to the endpoints website

[misca2] 16/3/2021 16:45

The European Union's top drug regulator said it is still firmly convinced that the benefits of AstraZeneca PLC's Covid-19 vaccine outweigh the risks, after a string of nations in the bloc temporarily halted use of the shot over blood-clot concerns.

The European Medicines Agency so far sees no indication that the vaccine caused a small number of blood-clotting incidents reported across the region, Executive Director Emer Cooke said in a briefing Tuesday.

The regulator is currently reviewing those incidents to determine whether they represent a broader risk. Ms. Cooke said the results of the review would be presented Thursday.

The vaccine, which was developed jointly with the University of Oxford, hasn't been approved in the U.S. AstraZeneca is expected to apply for authorization for emergency use once it submits results from Phase 3 human trials conducted in the U.S. Those trials are due as early as this month.

Tuesday's briefing followed moves by a growing number of European countries over the past week, including Germany, Italy, France and Spain, to halt use of the vaccine pending an examination of reported blood clotting in a small number of people who received it. Officials in those countries said they were awaiting a full review of those cases, which regulators say have been less prevalent than expected rates of severe clotting in the general population.

Ms. Cooke said that blood-clot incidents remain very rare.

"Trust in the safety and efficacy of the vaccines...is paramount for us, " Ms. Cooke said. "We are worried there may be an effect on the trust of the vaccines."

She said the attention on blood clots, which are known generally as venous thromboembolic events, has produced more reports as attention to them spreads. The agency's review is focused on the AstraZeneca vaccine but is also looking at reports of clotting in people who have received other vaccines, including one developed by Pfizer Inc. and BioNTech SE. Instances of severe clotting have been rare across all vaccines, she said.

The regulator is being asked to determine whether there is evidence that vaccination and severe blood clots are connected, and potentially update its guidance, if warranted. The regulator has said it isn't yet in a position to predict a conclusion but is sticking with advice to continue using the AstraZeneca vaccine.

The precautionary halts to the AstraZeneca vaccine's use in European countries contrasts with recommendations by the European and U.K. regulators to continue using the shot. The partial pullback is dealing another blow to the continent's sluggish vaccination rollout, which has suffered supply shortages and other problems.

Europe is grappling with rising numbers of Covid-19 cases. Its vaccination rates are far lower than in the U.S. and the U.K., where cases have stabilized or are falling.

Write to Jenny Strasburg at [e-mail]



(END) Dow Jones Newswires

March 16, 2021 11:15 ET (15:15 GMT)

[philanderer] 16/3/2021 14:15

Afternoon EI, spot on with that summary.

[essentialinvestor] 16/3/2021 14:02

Some of the amateur shorts will have taken a bath today, very silly.

AZN trading at a level which ascribes 0 value to any COVID future revenues,
which whilst a pandemic is ongoing are not on commercial terms in any case.

Unfortunately some may have difficulty relating to this. AZN = an oncology play,
at least before the Alexion deal completes.

[essentialinvestor] 16/3/2021 14:00

Yup, you can look at current consensus 2 yesrs out, tells the same story.

[beckers2008] 16/3/2021 13:56

BARCELONA (Agefi-Dow Jones) - According to Jefferies, AstraZeneca's revenue and profit trajectory is compelling compared to that of its largely capitalized European counterparts. The quality of earnings and cash flow generation of the British pharmaceutical giant are improving while the trajectory of earnings per share is considered "impressive" by Jefferies who raises its recommendation on the title from "hold" to "buy". According to the investment bank, the $ 37 billion transaction to acquire Alexion also has strategic advantages for AstraZeneca. The acquisition will allow the company to enter the "attractive" rare disease segment and it will also develop its ability to fund greater R&D spending and maximize the value of its pipeline, according to Jefferies. In London, the AstraZeneca share gains 3.2% to 72.04.

[umitw] 16/3/2021 13:15

I think this is due to Brexit, EU trying to get their own back.Unfortunately the damage is done and the reputation of AZN is on the line.Bad play EU.!

[bluemango] 16/3/2021 12:49

#4342 Indeed.

The irony is, if anyone looks at this purely from a statistical viewpoint (so ignoring the complete lack of any known scientific mechanism that could possibly link the two), you'd have to conclude (comparing incidence with vaccine, against population at large) the vaccine makes you LESS likely to have a blood clot.

[mr hangman] 16/3/2021 12:46

The biggest problem the EU have with the OxfordAZ vaccine, it's BRITISH

[philanderer] 16/3/2021 12:39

Do they tell us everything ?

[thamestrader] 16/3/2021 12:29

What evidence are all these countries' experts seeing that the WHO/EMA/MRHA/AZN/ETCs' experts are not seeing? They can't both be right.

I heard someone on the TV/radio say that (a) blood clot frequencies were exactly the same as with the pfizer jabs, and (b) were actually slightly lower than the population at large.

[philanderer] 16/3/2021 11:09

Sweden halts AstraZeneca vaccine use

[philanderer] 16/3/2021 10:58

EI, nice trade, well done.

-------------------------

I thought theyd given it the thumbs up ?

WHO’s global advisory committee on vaccine safety will hold a meeting on Tuesday, while the European Medicines Agency (EMA) will also meet, with a view to publishing further guidance on Thursday.

Yahoo Finance

[imastu pidgitaswell] 16/3/2021 10:16

I'm sitting on last week's purchases for the moment, but that can change at any moment...

[triple witcher] 16/3/2021 10:12

This could be the reason for part of the rise JEFFERIES RAISES ASTRAZENECA TO 'BUY' (HOLD) - PRICE TARGET 8,850 (8,250) PENCESold my two short term buys today as documented on this board at 7205Still hold my larger holding for the longer term